Supernus Pharmaceuticals Faces Downgrade Amid Prescription Concerns
![Supernus Pharmaceuticals Faces Downgrade Amid Prescription Concerns](https://investorshangout.com/images/blog/ihnews-Supernus%20Pharmaceuticals%20Faces%20Downgrade%20Amid%20Prescription%20Concerns.jpg)
Overview of Recent Developments at Supernus Pharmaceuticals
Piper Sandler has recently downgraded Supernus Pharmaceuticals Inc (NASDAQ: SUPN) due to slower than anticipated growth in prescriptions for Qelbree, the company's top-selling ADHD medication. This decision stems from the surprising lack of an expected increase in Qelbree prescriptions as students return to school.
Qelbree's Current Performance
Qelbree (viloxazine) is designed for treating attention deficit hyperactivity disorder (ADHD) in both children and adults. In the second quarter, the sales figures reflected a significant year-over-year growth—up 92% at $59.4 million. Moreover, the total number of prescriptions reached 184,342, marking a 26% increase. However, despite these promising numbers, the anticipated surge during the back-to-school season has not occurred, leading to a re-evaluation of future sales projections.
Analyst Insights on Future Sales
The Piper analyst highlighted the management's recent focus on enhancing Qelbree's economic aspects, which includes reducing copayment assistance. This movement suggests that the growth trajectory of future prescription volumes may not be as strong as once predicted. While earlier estimates anticipated peak sales to approach $500 million, the analyst now considers $400 million a more plausible expectation.
Prescriptions Trends
Year-to-date, Qelbree prescriptions have surged by 91% in 2023 compared to the previous year. Nonetheless, the latest quarter has seen only a 1% increase in prescriptions in Q3, after a modest gain of 4% in Q2. In parallel, the ADHD medication market overall has faced a downturn, with a reported 2% decrease in prescriptions.
FDA Activities and Future Prospects
In recent updates, the FDA has accepted the resubmission of the new drug application (NDA) regarding Supernus’s apomorphine infusion device (SPN-830). This device is intended for managing motor fluctuations in patients with Parkinson’s disease. The upcoming user fee goal date (PDUFA date) for this application is set for February 2025. In April, the FDA had previously sent a Complete Response Letter, which indicated the need for additional product quality information.
Current Market Position
After the downgrade, Piper has adjusted its recommendation for Supernus Pharmaceuticals from Overweight to Neutral, assigning a target price of $36, decreased from $41. This adjustment reflects changing market conditions and the performance of Qelbree, which continues to show growth despite the adjustments in sales expectations.
Impact on Stock Performance
As of the latest reports, SUPN stock has seen a decline, dropping 7.17% to resting at $31.09. Investors remain watchful of both market trends and the ongoing developments in the pharmaceutical sector, particularly those impacting ADHD medications and related products.
Frequently Asked Questions
What factors contributed to Supernus Pharmaceuticals' downgrade?
The downgrade was primarily due to a slower-than-expected growth in Qelbree prescriptions.
How did Qelbree perform in the recent quarter?
In the second quarter, Qelbree's sales rose by 92% compared to the same quarter last year, totaling $59.4 million.
What are the new projections for Qelbree's sales?
The analyst has revised the peak sales expectation for Qelbree to $400 million, down from earlier estimates of $500 million.
What is the significance of the FDA resubmission for SPN-830?
The FDA has accepted the NDA resubmission for SPN-830, which is important for the treatment of motor fluctuations in Parkinson’s disease, with a review date set for February 2025.
How has the stock reacted to the downgrade?
Following the downgrade, SUPN stock has decreased by 7.17%, reflecting ongoing concerns about prescription growth and market position.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Vanda Pharmaceuticals Set to Join 2024 Global Healthcare Conference
- Haivision Delivers Strong Q3 Results Amid Growth Focus
- Oracle America Faces $115 Million Class Action Settlement
- Oxford Industries Faces 7% Drop After Q2 Earnings Report
- Hurricane Francine Impacts Louisiana Oil Refineries Amid Storm Threat
- Kewaunee Scientific Reports Strong Q1 Results Amid Challenges
- Teva Pharmaceuticals to Showcase Innovations at Key Healthcare Event
- Market Movements as Tech Drives Stocks Higher Amid Inflation Data
- Oxford Industries Faces Stock Decline Despite Solid Earnings Report
- Meiwu Technology Faces Nasdaq Compliance Challenge as Shares Fall
Recent Articles
- Jensen Huang Discusses Customer Frustrations Over Chip Demand
- Landbase Secures $12.5M to Transform Go-To-Market Strategy
- Johnson & Johnson Faces Major Copyright Battle Over Music Use
- Why ResMed Stock Remains a Strong Portfolio Choice Today
- Stock Markets React to Oil Inventory Updates and Economic Trends
- Paragon 28 Unveils Innovative Right-Angle Drill for Ankle Surgery
- Summit Healthcare REIT, Inc. Achieves Remarkable Asset Sale Success
- Understanding Recent Securities Fraud Claims Against Agenus, Inc.
- Oracle Enhances Multicloud Services with Major Partners
- Transforming Patient Monitoring: Trends in Emerging Technologies
- Market Movers: Nvidia and First Solar Soar Amid Market Swings
- Legal Challenge Against Rio Tinto's Arizona Copper Project
- Boeing Prepares for Possible Strike Amid Worker Unrest
- Goldman's Strategic Shift: Navigating Credit Card Partnerships
- US Bank Executives Forecast Gloomy Growth with Investment Insights
- Cautious Outlook from Top U.S. Banking Executives Amid Challenges
- Market Moves: Insight into LUV Options Trading Trends
- Understanding BP's Recent Bullish Trends in Options Trading
- Insights into Nucor's Options Trading and Market Position
- Exciting Developments Propel Nano Nuclear Shares Higher Today
- Glaukos Corporation Thrives with Strong Demand for Innovative Solutions
- Transform Your Investment: Discover the Power of Compounding
- Significant Growth: A Look at Ingersoll Rand's Stock Journey
- Aequum Capital Strengthens Leadership with James Farrell's Expertise
- SWAPA President Discusses New Aviation Safety Initiatives
- SolarTech Strengthens Leadership with Strategic Board Enhancements
- SINEXCEL Launches Innovative Energy Solutions at RE+ 2024
- Global Water Desalination Market Set for Major Expansion
- Understanding Oracle's Recent 20-Day Moving Average Breakthrough
- Understanding Immunovant's Bullish Options Trading Insights
- Understanding the Recent Surge in Wynn Resorts Options Activity
- NEXT's Neuro-Literacy Program Gains Official Accreditation
- Understanding GE Vernova's Recent Options Activity and Insights
- SLB Revolutionizes Lithium Extraction for Eco-Friendly Future
- Valet Living Elevates Matt Graves to President and COO Role
- Exciting Potential for Viking Therapeutics as Stock Gains Momentum
- Connect with Leaders at the Upcoming Compliance Conference
- Wellesley Information Services Expands Global ERP Capabilities
- Nth Degree's Partnership with Shamrock Fuels Event Growth Strategy
- Daniel Stark Law Celebrates Major Recognition for 2023 Verdicts
- FDA Takes Action Against Chinese Labs for Serious Violations
- Anticipating Earnings: Key Players Set to Reveal Results
- PPI and Jobless Claims: What They Mean for the Market Today
- Insights from a Former Google Exec on Competitive Strategies
- Starbucks CEO Brian Niccol Charts a Path to Recovery
- Vocodia Holdings: Strategic Initiatives for Future Growth
- Stryker Launches Innovative Foot & Ankle Medical Solutions
- Understanding Zscaler's Current Options Market Trends
- Understanding Newmont's Options Trading Activity and Insights
- Insightful Overview of Bank of America's Options Activity Trends